Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly’s dominance
RSS SUMMARY · AGGREGATED FROM CNBC
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
US
Micron and Qualcomm are among the most overbought stocks this week. Here are the others
CNBC·9h ago·3 min read
Health
MV Hondius hantavirus outbreak: A luxury expedition cruise boom and new world of remote travel risks
CNBC·9h ago·3 min read
Business
Why one of the nation’s largest auto lenders isn’t worried about high vehicle prices or ‘forever loans’
CNBC·10h ago·3 min read
US
U.S. sanctions companies and individuals in the Middle East and China for helping Iran
CNBC·11h ago·3 min read
Related
On this beat
Business
Lucky Strike Accused of Racking Up a Bowling Monopoly
INC·37m ago·3 min read
Business
American Airlines sees $341 million hike in Q1 jet fuel costs
THE STREET·1h ago·3 min read
Business
How Maury Povich Outlasted the Daytime TV Wars Using This 1 Business Framework
INC·2h ago·3 min read
Business
A nutritionist stocks up on 12 ingredients to effortlessly add protein, fiber, and vitamins to his meals
BI·1h ago·3 min read